Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Prostatic Neoplasms Clinical Trial

— ADAM  

Official title:

A Randomized, Open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04295447
• Other study ID #: UKM17_0018
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 10, 2020
• Est. completion date: November 30, 2028

Study information

• Verified date: June 2024
• Source: Universität Münster
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after radical prostatectomy (RPE) in comparison to standard of care (SOC).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 190
• Est. completion date: November 30, 2028
• Est. primary completion date: November 30, 2028
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent form (ICF).

2. Men = 18 years of age.

3. Patients with histologically confirmed adenocarcinoma of the prostate after radical prostatectomy.

4. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1.

5. Exclusion of metastatic disease by computed tomography (CT)-scan of abdomen (magnetic resonance imaging (MRI) of abdomen is possible) and bone scan prior to study inclusion. A PSMA PET-CT/MRI is possible. In this case it has to be done with a diagnostic CT/MRI with contrast media and not with a low dose CT-scan only. In case PSMA-PET imaging has been done, a bone scan can be omitted. CT/MRI, and bone-scan imaging or PSMA PET-CT/MRI administered =12 weeks before RPE may be used for screening.

6. Patients after radical prostatectomy must meet the d'Amico criteria for high risk of disease recurrence: i.e. one of the following after RPE: 1) Gleason score =8, any T-stage, any initial PSA (iPSA) or 2) Gleason score 6 or 7, any iPSA and =pT3c or 3) iPSA >20 ng/ml, any Gleason score, any T-stage.

7. Patients have to have recovered from radical prostatectomy within four weeks to be able to take part in the study.

8. PSA-value must have declined below 0.2 ng/ml prior to randomization

9. Adequate hematologic, hepatic, and renal function:

Hematologic

• Haemoglobin =9.0 g/dL independent of transfusions
• Neutrophils =1.5 Ths./µL

Hepatic:

• Total bilirubin =1.5X upper limit of normal (ULN) [except for subjects with documented Gilbert's disease in which case total bilirubin not to exceed 10X ULN]
• Alanine (ALT) and aspartate (AST) aminotransferase =2.5X ULN

Renal:

• Serum creatinine <1.5X ULN or calculated creatinine clearance =50 mL/min
• Serum potassium =3.5 mM
• Serum albumin = 3.0 g/dL.

10. Ability to swallow study medication tablets.

11. In case of apalutamide treatment: Agrees to use a condom and another highly effective method of birth control if he is having sex with a woman of childbearing potential or to use a condom if he is having sex with a woman who is pregnant

Exclusion Criteria:

1. Any chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone q.d.

2. Prior cytotoxic chemotherapy or biologic therapy for the treatment of prostate Cancer.

3. Prior or current treatment of prostate cancer with apalutamide, enzalutamide, darolutamide, or other investigational agents targeting the androgen receptor.

4. Prior therapy with Sipuleucel-T or other vaccination or immunogenic therapy for the treatment of prostate Cancer.

5. Prior treatment with abiraterone acetate or other androgen synthesis inhibitors (e. g. ketoconazole, TAK700, TOK001).

6. Use of 5-a reductase inhibitors (eg, dutasteride, finasteride) =4 weeks prior to randomization.

7. Prior surgical castration or medical castration using LHRH-Agonists or GnRH-Antagonists.

8. Prior or current radiation or radionuclide (including radium-223 dichloride) therapy for treatment of prostate cancer (adjuvant radiation of the prostate bed without involvement of the regional lymph node template as by standard of care in case of positive surgical margins (R1) is allowed).

9. Prior or current systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of Cycle 1, Day 1.

10. Any lymph node or distant metastasis.

11. History of seizure or condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness =1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).

12. Current or prior treatment with anti-epileptic medications for the treatment of seizures.

13. Management of cardiovascular risk factors, such as hypertension, diabetes or dyslipidaemia should be optimised as per standard of care before treatment with apalutamide will be initiated 13.1. Uncontrolled hypertension (systolic BP =140 mmHg or diastolic BP =90 mmHg. For patients with relevant comorbidities (e.g. diabetes) systolic BP =130 mmHg or diastolic BP =80 mmHg). Patients with a history of hypertension are allowed provided that blood pressure is controlled by anti-hypertensive Treatment 13.2. Patients with uncontrolled diabetes defined as HbA1c =7.5% 13.3. Patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl. For patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl and SCORE-value of 1-5%: In case of a SCORE-value of <1% a LDL cholesterol level of up to 115 mg/dl is acceptable. In case of increased LDL cholesterol above these values a statin-therapy can be initiated and a rescreening within 4 weeks is possible 13.4. Cardiovascular risk assessment via an appropriate score (e.g. the SCORE-Chart for the European high/low risk score from the European Society of Cardiology) and = borderline risk i.e. 10% of developing cardiovascular events within 10 years without prior established cardiovascular disease

14. Active or symptomatic viral hepatitis or chronic liver disease or HIV.

15. History of pituitary or adrenal dysfunction.

16. Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of <50% at baseline.

17. Any condition that requires treatment with digoxin, digitoxin, and other digitalis drugs.

18. Long QT-Syndrome.

19. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy.

20. Other malignancy with a =30% probability of recurrence within 24 months, except non-melanoma skin Cancer.

21. Any condition, which, in the opinion of the investigator, would preclude participation in this trial.

22. Gastrointestinal conditions affecting Absorption.

23. Hypersensitivity to the active substance, or to any of the excipients of the study medication.

24. Any psychological, cognitive, familial, sociological or geographical condition that, in the investigator's opinion, compromises the patient's ability to understand the patient information, to give informed consent or to comply with the study protocol.

25. Participation in another interventional clinical trial during this trial or within 4 weeks before entry into this trial. There may be exceptions at the discretion of the (coordinating) investigator.

Related Conditions & MeSH terms

• Prostatic Neoplasms

Intervention

Other:
• Standard of care
Observation only or An optional adjuvant radiation of the prostate bed in case of positive surgical margin

Drug:
• Apalutamide 60Mg Tab
(4 x 60 mg) once daily on days 1-28 of a 28-day cycle

Locations

Country	Name	City	State
Austria	Medizinische Universität Innsbruck	Innsbruck
Austria	Ordensklinikum Linz GmbH Elisabethinen	Linz
Austria	Uniklinikum Salzburg, Landeskrankenhaus	Salzburg
Austria	Hanusch-Krankenhaus	Wien
Germany	Universitätsklinikum Augsburg Klinik für Urologie	Augsburg
Germany	GFO Kliniken Rhein-Berg	Bergisch Gladbach
Germany	Urologicum Duisburg	Duisburg
Germany	Universitätsklinikum Düsseldorf	Düsseldorf
Germany	Universitätsklinikum Essen	Essen
Germany	Universitätsklinikum Frankfurt	Frankfurt
Germany	St. Antonius-Hospital Gronau GmbH Klinik für Urologie, Kinderurologie und Urologische Onkologie	Gronau
Germany	Universitätsklinikum Jena	Jena
Germany	Urologische Partnerschaft Köln	Köln
Germany	KLINIKUM LANDSHUT gemeinnützige GmbH	Landshut
Germany	Klinikum Leverkusen gGmbH, Klinik für Urologie	Leverkusen
Germany	Universitätsklinikum Schleswig-Holstein, Campus Lübeck	Lübeck
Germany	Universitätsklinikum Magdeburg	Magdeburg
Germany	University Hospital Münster	Münster	North Rhine-Westfalia
Germany	Klinik für Urologie, Lehrstuhl Regensburg, Am Caritas Krankenhaus St. Josef	Regensburg
Germany	Helios Universitätsklinikum Wuppertal, Universität Witten/Herdecke	Wuppertal
Germany	UroGynZentrum	Wuppertal

Sponsors (2)

Lead Sponsor	Collaborator
Universität Münster	Janssen Pharmaceutica N.V., Belgium

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS).	This endpoint is defined as time interval from randomization until BCR (irrespective of the PSADT), metastases, or death from any cause, whichever occurs first. BCR is defined as a PSA = 0.2 ng/ml that has risen on at least two separate occasions at least four weeks ± 3 days apart and measured by the central PSA-lab. The time of BCR is then backdated to the time of the first increased PSA measurement.; Metastatic disease will be defined as the presence of bone metastases visualized on bone scan prostate cancer working group 3 (PCWG3)-criteria; and/or visceral (e.g. liver, lung, brain) or extra-pelvic nodal metastases visualized on CT scan (or MRI scan) (RECIST 1.1-criteria). Evaluations will be performed every 6 months once BCR occurred or sooner if clinically indicated.; For a patient with none of these events before the end of follow-up, observation of PFS will be censored at the date of his date of last contact.	From date of randomization until the date of first documented progression (BCR or metastases) or date of death from any cause, whichever came first, assessed up to 7 years"
Secondary	PSA doubling time (PSADT)	In case of a BCR, PSA kinetics as the PSADT are calculated based on the monthly PSA measurements during the first six months after the BCR. The values used to determine the BCR are included in the calculation of PSA kinetics as well.; PSADT is calculated according to Pound et al. by the natural log of 2 (0.693) divided by the slope of the relationship between the log of PSA and time of PSA measurement (i.e. time from BCR) for each patient [33]. PSADT can also be assessed using the MSKCC PSADT calculator (https://www.mskcc.org/nomograms/prostate/psa_doubling_time) using the above definitions.	If BCR occurs up to 6 months later
Secondary	Incidence of Adverse Events [Safety and Tolerability]	Safety and tolerability assessed on the basis of adverse events, more precisely adverse events, serious adverse events, adverse reactions, and serious adverse reactions	From date the informed consent is signed until BCR occured and PSADT was calculated or when distant metastasis occurred (both with or without BCR) or date of death from any cause, whichever came first, assessed up to 7 years.